Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients